MAPK3 and neoplasm: For example, activation of ERK1/2 by activated mutant HRAS drives NOXA mRNA and protein expression, whereas inhibition of ERK1/2 signalling in tumour cells with pathway deregulation, such as BRAF600E in melanoma, reduces NOXA levels 69, 70, 71, 72, 73.